Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Topp

Showing results (121-130 of 308) with videos related to

Pageof 31
Sort By:
Transplantation|September 16, 2003
Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantationK S Topp, P L Painter, S Walcott, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 15, 1996
Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomesM L Grimes, J Zhou, E C Beattie, et al.
Leukemia|October 10, 2017
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemiaM S Topp, M Stelljes, G Zugmaier, et al.
Blood Cancer Journal|September 6, 2014
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemiaG Zugmaier, M S Topp, S Alekar, et al.
Blood|October 24, 2002
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effectLaurence J N Cooper, Max S Topp, Lisa Marie Serrano, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Cancer|May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesHagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Haematologica|January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemiaNicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Pageof 31

Showing results (121-130 of 308) with videos related to

Sort By:
Pageof 31
Transplantation|September 16, 2003
Alterations in skeletal muscle structure are minimized with steroid withdrawal after renal transplantationK S Topp, P L Painter, S Walcott, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 15, 1996
Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomesM L Grimes, J Zhou, E C Beattie, et al.
Leukemia|October 10, 2017
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemiaM S Topp, M Stelljes, G Zugmaier, et al.
Blood Cancer Journal|September 6, 2014
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemiaG Zugmaier, M S Topp, S Alekar, et al.
Blood|October 24, 2002
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effectLaurence J N Cooper, Max S Topp, Lisa Marie Serrano, et al.
Hematological Oncology|March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyGiovanni Martinelli, Nicolas Boissel, Patrice Chevallier, et al.
Cancer|May 5, 2016
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesHagop M Kantarjian, Anthony S Stein, Ralf C Bargou, et al.
Haematologica|January 14, 2017
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemiaNicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Pageof 31